AVDL vs. DAWN, DVAX, PCRX, MORF, AKRO, ANIP, LGND, KNSA, GMTX, and RCUS
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Day One Biopharmaceuticals (DAWN), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), Morphic (MORF), Akero Therapeutics (AKRO), ANI Pharmaceuticals (ANIP), Ligand Pharmaceuticals (LGND), Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry.
Day One Biopharmaceuticals (NASDAQ:DAWN) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 10 mentions for Day One Biopharmaceuticals and 9 mentions for Avadel Pharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.53 beat Avadel Pharmaceuticals' score of -0.01 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
Avadel Pharmaceuticals has higher revenue and earnings than Day One Biopharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Day One Biopharmaceuticals has a beta of -1.44, meaning that its stock price is 244% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 8.4% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Day One Biopharmaceuticals currently has a consensus target price of $37.67, suggesting a potential upside of 132.94%. Avadel Pharmaceuticals has a consensus target price of $24.17, suggesting a potential upside of 56.01%. Given Avadel Pharmaceuticals' higher possible upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than Avadel Pharmaceuticals.
Day One Biopharmaceuticals has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -284.42%. Avadel Pharmaceuticals' return on equity of -57.28% beat Day One Biopharmaceuticals' return on equity.
Avadel Pharmaceuticals received 298 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 65.22% of users gave Avadel Pharmaceuticals an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.
Summary
Day One Biopharmaceuticals and Avadel Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
